glp-1 obesity drug news oct 21 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth Why GLP-1 drugs are changing

j , Change in body weight

Not necessarily back to baseline, but the trajectory of weight regain is more rapid the more weight you lose

Statins remain the gold-standard first-line treatment for elevated LDL cholesterol, capable of reducing LDL levels by 3050% depending on dose and agent

Sadler K, Arnold F, Dean S

Were excited to help consumers access one of the most anticipated weight-loss treatments on the market, Wendy Barnes, President and CEO of GoodRx, said in a news release

Wegovy is licensed in the UK in doses up to 2.4mg for weight loss and, on 14 September 2025, Novo Nordisk published results of a phase IIIb clinical trial (STEP UP, NCT05646706) of a 7.2mg dose of semaglutide for subcutaneous injection 1